CRISPR gene editing captured headlines in recent months with the landmark approval of Casgevy, the first medicine made from the Nobel Prize-winning technology. But that milestone was only part of a larger story, of which an emerging generation of drugmakers hope to play a part.
Many of these newer companies were built to address CRISPR’s limitations. Some are advancing more precise forms of gene editing or working on better ways to deliver the complex medicines, for instance.
